A structured physician-led weight reduction program cut 12-month AF recurrence by 47% (risk ratio 0.53) following catheter ablation, while nurse-led care that improved guideline adherence without structured delivery showed no primary endpoint benefit. SGLT2i reduced recurrence across BMI strata despite modest weight loss — but only in patients with type 2 diabetes or heart failure, not in metabolically healthy individuals. GLP-1 receptor agonists produced greater weight loss yet yielded inconsistent recurrence outcomes, with Mendelian randomization indicating their cardiac benefit is largely BMI-mediated rather than weight-independent.
What makes this analysis genuinely useful is the mechanistic framework it proposes: two partly separable atrial substrates — one obesity-driven and structurally responsive to fat loss, another metabolic-inflammatory and selectively responsive to SGLT2i via mechanisms including reduced atrial fibrosis, oxidative stress, and hemodynamic unloading. This maps onto emerging electrophysiology research showing that atrial remodeling is not monolithic. The clinical implication is significant: practitioners may be systematically under-stratifying post-ablation patients by metabolic phenotype, missing opportunities to pair interventions that are complementary rather than interchangeable.
Critical caveats apply heavily here. This is a narrative review — cross-study comparisons rather than direct mediation analysis — meaning confounding is uncontrolled and the two-substrate model remains hypothesis-generating. Nevertheless, as a conceptual scaffold for designing prospective trials with phenotype-stratified randomization, this framework is a meaningful incremental advance over the prevailing one-size-fits-all approach to AF risk factor management.